Follow 8-year-old Martin and his family as they navigate daily life with type 1 diabetes, from meal adaptations to school activities, showing resilience and optimism.

At the dawn of his fifties, Philippe has tamed the diabetes he has lived with for over 25 years, along with his initial fear of injections. For him, this disease represents "a turning point, not an end." He leads a life "like everyone else," multiplying passions and fully enjoying every moment.

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.¹